Hawaii Biotech Initiates Phase I West Nile Vaccine Trial
Posted on: Tuesday, 24 June 2008, 09:03 CDT
Hawaii Biotech has initiated a Phase I clinical trial study with its West Nile vaccine candidate. The study, being conducted with healthy subjects, is the first clinical trial for the company.
This clinical study, which will be recruiting volunteers for four treatment groups, is being conducted at a Phase I trial site in Honolulu. Results should be known within a year, the company said.
The first phase of a clinical development program is designed to assess safety, determine a dosage range and identify potential side effects. There are two additional clinical phases prior to FDA registration and a fourth post-marketing phase to gain additional information.
The Hawaii Biotech West Nile vaccine candidate is a recombinant sub-unit vaccine developed with the intent to induce protective immunity in recipients.
Elliot Parks, president and CEO of Hawaii Biotech, said: "This clinical study is an important milestone in Hawaii Biotech's maturation into a clinical stage company."
Source: Datamonitor
Related Articles
- MedImmune Initiates Phase I/IIa RSV Vaccine Trial
- Novavax Completes Enrollment in Phase IIa Influenza Vaccine Trial
- Bionor Immuno Initiates Phase IIb HIV Vaccine Trial
- Sinovac Initiates Volunteer Enrollment in Phase II Flu Vaccine Trial
- Emergent Initiates US Phase II Typhoid Vaccine Trial
- Hemispherx Completes Enrollment in Phase II Flu Vaccine Trial
- Sinobiomed to Initiate Phase II Malaria Vaccine Trial
- South Africa to host phase II AIDS vaccine trials
- China's Phase One AIDS Vaccine Trial Nears End
 |
 |
User Comments (0)
RSS Feeds